



Environmental Health & Safety

777 GLADES ROAD, 112 CAMPUS OPERATIONS
BOCA RATON, FLORIDA 33431-0991
(561) 297-3129, FAX (561) 297-2210
Email: ehs@fau.edu Web Page: www.fau.edu/ehs

FAX TRANSMITTAL

To: The Sunshine Project
From: ^{DW} Darlene Ward, BSO
Date: April 28, 2006
Pages: 10 Including Cover

Re: The IBC Minutes

Two letters were faxed to me indicating a request for IBC minutes from Florida Atlantic University and Scripps Florida Research Institute but there is only one IBC registered with the NIH to review proposals from Florida Atlantic University and Scripps Florida Research Institute. Please contact me if you have any questions.

Thank you.



Environmental Health & Safety

777 GLADES ROAD, 112 CAMPUS OPERATIONS

BOCA RATON, FLORIDA 33431-0991

(561) 297-3129, FAX (561) 297-2210

Email: ehs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee

February 16, 2006 at 3:00 PM

123 Biomedical Science

Meeting Minutes

Members Present: Dr. David Binninger, Dr. Howard Prentice, Darlene Ward, Kathy Hoelscher-Levine, Dr. Vijaya Iragavarapu-Charyulu, Dr. Herbert Weissbach, by Teleconference: Dr. Don Mosier, Dr. Donny Strosberg
Members Absent: Dr. Michael Conkright, Charles Williamson

Dr. Prentice asked the members to introduce themselves to Dr. Mosier who was joining our meeting for the first time via teleconference from La Jolla. Next, the members approved the minutes from the last meeting.

Dr. Prentice opened the discussion for the consideration of Dr. Timothy Tellinghuisen's proposal entitled Characterization of the NS5A protein of Hepatitis C Virus. The committee members discussed the biosafety procedures and Ms. Ward briefed the members on the survey of the lab space. At this time, there will be two BSL2 projects and possibly a third experiment in the laboratory suite so standard operating procedures addressing PPE and entering and exiting procedures need to be developed so that all researchers are following uniform procedures. Dr. Mosier pointed out that although they will be working with the virus at first, the project calls for amplification of a single gene that is a non-infectious protein which can be done at BSL1. The PI outlined very explicit safety procedures and the members agreed to approved the project at BSL 2 containment.

The second protocol to be considered was Dr. Charles Weissmann's proposal entitled Experimental Model of Scrapies in Hamster. Ms. Ward pointed out that this protocol was similar the one he is doing now with mice. Dr. Iragavarapu-Charyulu questioned whether scrapie is non-infectious to humans since the PI stated it was unknown. Dr. Mosier stated the general assumption is that it does not cross species but one recent report documents that Chronic Wasting Disease has crossed over to primates raising a doubt about species transmission to human. The members approved the proposal at ABSL 2 containment with ABSL 3 work practices.

The last protocol to be considered was Dr. Charles Weissmann's proposal entitled Automated Processing of Scrapie Infected Cell Cultures. Ms. Ward stated that the robot has been built into a biosafety cabinet that has been certified and there is still work that needs to be done on software programming and decontamination issues to ensure the robot is working properly and safety measures are in place to protect the worker. Dr. Mosier wanted to know how the robot will be decontaminated when it is in need of repair since the harsh disinfectants that are required for prions would not be feasible. Ms. Ward stated this is something that still needs to be worked out and Dr Strosberg suggested asking the PI now since he was next to his office. Dr. Strosberg reported back to the members that the PI only anticipates the deck of the robot to be potentially contaminated which could be decontaminated with sodium hydroxide. Dr. Mosier stated with his experience, there may be localized aerosols generated right over the plate and with the sampling device so he suggest that engineering controls like plexiglass or direct vented containment be devised to limit dispersion of aerosols. The members decided to move ahead with approval at BSL2 but with the contingency that the PI submit a plan to the IBC on further engineering controls and decontamination procedures.

The next item on the agenda was to review and approve two new IBC registration forms for exempt rDNA projects and a form to work with human and non-human materials. The members approved the forms and they will be placed on the website and registration procedures will be updated.

Lastly, Ms. Ward briefed the members on two biosafety situations that occurred on the Boca campus. The first was an art display about biomedical research that was improperly thrown away and EH&S and the police responded to the scene. The student and teacher took responsibility to properly dispose of the display, while EH&S took the sharps away to dispose as biomedical waste. The second situation concerned a first ever shooting on campus that involved a large amount of blood in a remote location. After the police investigation, EH&S responded to the scene along with physical plant to clean up the blood spill. Having access to a water source was problematic during the clean up so plans are being made to purchase a vehicle with water storage capability.

The committee meeting adjourned at approximately 4:05 PM.

Institutional Biosafety Committee

November 3, 2005 at 3:00 PM

123 Biomedical Science

Meeting Minutes

Members Present: Dr. David Binnering, Dr. Michael Conkright, Dr. Howard Prentice, Darlene Ward , Kathy Hoelscher-Levine, Dr. Vijaya Iragavarapu-Charyulu, Dr. Donny Strosberg, Dr. Herbert Weissbach
Members Absent: Dr. Zhongwei Li, Charles Williamson

Two new committee member's Dr. Conkright and Dr. Strosberg were welcomed to the IBC by Dr. Prentice and introduced to each member. In addition, Dr. Prentice asked the members if they approved minutes from the last meeting and the minutes were approved.

Ms. Ward gave the committee an overview of the final agreement on the dual FAU/Scripps IBC review process. The addition of the new members will enhance the dual approval process for Scripps Florida research projects. The changes to the IBC were sent to NIH for annual registration and a letter was sent back from NIH approving the new process and registration. Dr. Weissbach inquired as to when Scripps will get their own IBC and was informed that it will happen when they move to their permanent location.

Next, Dr. Prentice spoke about the IBC registration process and registration forms and the need to make this registration easy to do to ensure that more PIs will comply with the procedures. Ms. Ward had prototypes from other institutions that the members reviewed and spoke about. It was decided that Ms. Ward will make a rDNA exempted form for those projects that do not require full committee approval and she will also develop a form for those working on human cell lines and blood. One form has already been completed for projects that required addendums or modification and the members discussed the form and voted to approve the form.

Subsequently, the committee discussed projects that were recently approved and listed on the agenda. Ms. Ward spoke about Dr. Shibata's listeria project and how hurricane Wilma damaged Building T-8 after it was renovated for his project. His project will have to be moved to the small vivarium and plans are being worked out to do the project in room 110. Biobubbles have been purchased for the mice and SOPs are being revised to reflect location change. Furthermore, Ms. Ward informed the member's that Dr. Li's DOD project is up for renewal and DOD will be coming to campus for a reinspection of his lab. Next, Ms. Ward spoke about the robot that is being installed in the BSL3 anteroom for the mouse scrapies project which will mean two projects will take place in this lab. Dr. Strosberg expressed concern about work space issues for Scripps Florida and that the setup in the containment suite is not ideal but will work until the new building is completed.

Lastly, Ms. Ward informed the members of a communicable disease outbreak on the Boca campus involving MRSA. She explained how it happened and the preventative measures such as education, clean up, and hand washing that were put in place to control the spread of bacteria and prevent reoccurrences. Ms. Hoelscher-Levine explained how this problem started out in hospitals and is now common in the community particularly in athletic facilities.

The committee meeting adjourned at approximately 3:50 PM.



Environmental Health & Safety

777 GLADES ROAD, 112 CAMPUS OPERATIONS

BOCA RATON, FLORIDA 33431-0991

(561) 297-3129, FAX (561) 297-2210

Email: chs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee

July 28, 2005 at 3:30 PM

123 Biomedical Science

Meeting Minutes

Members Present: Dr. David Binninger, Dr. Zhongwei Li, Dr. Harry Orf, Dr. Howard Prentice, Darlene Ward

Members Absent: Kathy Hoelscher-Levine, Dr. Vijaya Iragavarapu-Charyulu, Dr. Herbert Weissbach, Charles Williamson

Committee members approved the minutes from the last meeting and began discussing the dual FAU/Scripps IBC review process. Dr. Orf stated that the spirit of the initial agreement did not consider the time associated with two separate IBC reviews and the extensive amount of research taking place. As a result, LaJolla and FAU decided to revise the agreement by expanding FAU's IBC committee to include two faculty members from Scripps Florida and the IBC Chair from LaJolla to participate in the initial review and approval process thus saving time and enhancing the research approval procedures. Dr. Orf had asked to step down from the IBC since he was a good choice for the beginning of this agreement but they now have researchers with more technical expertise that could serve the committee better. Dr. Orf asked the IBC if he could choose the two committee members that will provide a good mix for the IBC. The IBC approved the change in the review and approval process for Scripps Florida and for Dr. Orf to choose the new members.

Subsequently, the members spoke about the role of community members and the issue of sharing members as alternates for both the IBC and IACUC. It was decided that this is a good idea, but at this time only the IACUC can easily do this as both FAU and Scripps Florida have IACUC committees. The IBC will have to enlist other community members to be alternates.

Next Dr. Prentice spoke about the IBC registration requirements for both exempted and BSL 1 projects. Since most researchers are not complying with this requirement unless they are flagged by EH&S or DSR, the committee needs to determine if these projects should still be registered with the IBC and decide the best method to do accomplish this task. Dr. Prentice and Dr. Orf mentioned that their past institutions registered these types of projects by using a one page form. The committee agreed that these projects still need to be registered with the IBC and Ms. Ward will revise the forms to make them easy to fill out and submit to the IBC.

Ms Ward informed the committee that the City of Boca sent a letter to her stating that they will not approve the second request for liquid waste discharge from the mouse scrapies project. The members discussed the concern of complying with regulations versus developing procedures that rely on inaccurate public perception. Dr. Orf stated that this issue needs to be resolved or risk jeopardizing research endeavors. The director of EH&S and the COB will meet on this issue to determine the best method of disposal.

Ms Ward reported that the BSL3 vivarium has been certified and commissioned and discussed moving the mouse scrapie project to the Jupiter site. Also, the upstairs BSL 3 still needs ventilation work before it is certified. In addition, EH&S and the EOC performed an Avian Flu Epidemic Tabletop Exercise to comply with the yearly training requirement. Lastly the Biosafety manual will be sent to everyone for review and approval.

The committee meeting was adjourned at approximately 5:10 PM.



FLORIDA ATLANTIC UNIVERSITY

777 GLADES ROAD, 112 CAMPUS OPERATIONS
BOCA RATON, FLORIDA 33431-0991
(561) 297-3129, FAX (561) 297-2210
Email: ehs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee
April 6, 2005 at 3:30 PM
123 Biomedical Science
Meeting Minutes

Members Present: Dr. David Binnering, Dr. Vijaya Iragavarapu-Charyulu, Dr. Zhongwei Li, Dr. Harry Orf, Dr. Howard Prentice, Darlene Ward and Visiting Scientist: Dr. John Hogenesch
Members Absent: Kathy Hoelscher-Levine, Dr. Herbert Weissbach, Charles Williamson

Committee members introduced each other to Dr. John Hogenesch who was meeting with the IBC to discuss project reporting issues to the IBC. Dr. Hogenesch asked the members if the requirements to register BSL1 projects with the IBC as outlined in the Scripps/FAU dual review process agreement can be tailored to fit his research needs. He stated that the registration of his 43,000 plasmids and 70 human and mouse cells lines with the IBC will present a major paperwork dilemma for him and the IBC. He explained that his genotechnology group will develop a repository that will be accessible to all biomedical and drug discovery Scripps' researchers. Dr. Binnering asked about the opportunity to turn this project into a collaboration with FAU researchers. A discussion ensued on how to report this research to the IBC. Dr. Hogenesch suggested approaching this on an institutional level and Dr. Orf pointed out that when the agreement was written, La Jolla did not realize the automated component and industrial level of research that will be taking place at ScrippsFL. A database on the web that the IBC members could access seemed to be the most efficient way to keep apprised of what research is taking place. Dr. Hogenesch is going to create a document where resources are located and have the PIs working on the materials sign off on it. He will have something for the committee before the next meeting.

Next the IBC discussed Dr. Griffin's drug testing program procedures. It has been determined that working in a Biosafety cabinet will provide adequate protection instead of using a chemical fume hood. Ms. Ward gave an over-view of biosafety issues. The Scripps research building was under too much negative pressure and the doors to the building were hard to open. Dr. Orf pointed out that after adjusting the exhaust fans and rebalancing the building, the doors are now easier to open. In addition, there were no sinks in place in the tissue culture labs so temporary handwashing areas have been set up to ensure hands are washed. Also reported was a water pipe leak that damaged the HEPA filters in a biosafety cabinet and the on-going process to get the BSL 3 vivarium and upstairs' laboratory ready for certification.

The committee members discussed Dr. Tam' SOP for his HIV work. The committee spoke about the HIV surveillance program and how it would be offered to all lab workers but they would have the option of waiving the test. The General Council is supposed to develop a liability/waiver form for HIV workers to complete. Dr. Iragavarapu-Charyule also pointed out this is how the hospitals offer HIV testing to employees. The committee members approved Dr. Tam's SOP and Ms. Ward will work with Dr. Tam to get his lab setup. A hands-free sink will be installed and the biosafety cabinets that he brought with him will need wire replacement and possibly HEPA filters replaced before they are certified and ready for use.

Lastly, Ms. Ward discussed the new Select Agent (SA) regulations that were published in March. She explained that the lists were modified and how those people working on SA were still exempted from registering their projects with the CDC/USDA. Dr. Orf asked if Ms. Ward could send out a notice to all Scripps PIs about the new regulations and request that they notify the committee if they are planning to work on any SA which will help to start registering some of the work. Dr. Li pointed out that it took him over a year to get his approval. Ms. Ward agreed to send out this notice. Dr. Prentice wanted to know if FAU researchers are also aware of the SA program and Ms. Ward stated that all researchers have reported their SA status and every new researcher is interviewed to see if they want to use SA in the lab.

The committee decided to wait until the summer to schedule the next meeting since most members do not know what their schedule will be at this time.

The committee meeting was adjourned at approximately 5:00 PM.



FLORIDA ATLANTIC UNIVERSITY

777 GLADES ROAD, 112 CAMPUS OPERATIONS
BOCA RATON, FLORIDA 33431-0991
(561) 297-3129, FAX (561) 297-2210
Email: ehs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee
January 24, 2005 at 3:30 PM
123 Biomedical Science
Meeting Minutes

Members Present: Dr. David Binnering, Kathy Hoelscher-Levine, Dr. Vijaya Iragavarapu-Charyulu, Dr. Zhongwei Li, Dr. Harry Orf, Dr. Howard Prentice, Darlene Ward, Dr. Herbert Weissbach
Members Absent: Charles Williamson

Committee members introduced each other to Dr. Harry Orf from Scripps FL, who is a new member of the IBC as part of Scripps dual IBC review process. The committee members discussed Dr. Tam's project entitled, HIV Fusion Inhibitors. Ms. Ward gave an overview of what was submitted thus far and spoke about the laboratory setup. The members discussed how this work can be done at BSL2 containment with BSL3 work practices. Dr. Weissbach wanted to know how long he has been working on HIV and if our IBC can get a copy of the approval letter from his previous institution. The committee also wants to see more detailed information on his Standard Operating Procedure (SOP) to include spill procedures, safe work practices and waste disposal methods and it was suggested to contact other institutions that are working on HIV to get a copy of their SOP. Ms Hoelscher-Levine wanted to make sure that the disinfectant for spills was appropriate for HIV as ethanol would not be adequate. Dr. Orf stated that he will contact Scripps to make sure that our spill procedures are similar to their procedures. Dr. Li also suggested that information on hurricane procedures be included in the SOP as this type of situation is something all of us have experienced.

The members also spoke about medical surveillance and whether serological testing should be done as a mandatory or voluntary requirement and if serum storage was a prudent practice. The members discussed that knowing the particular strains would be important to determine whether a workplace transmission could occur. Once we find out what other HIV researchers are doing, we can determine what should be required. Dr. Orf also discussed medical surveillance for Scripps personnel working in Jupiter and how a location must be found nearby. He suggested one medical center that contacted him and Ms Hoelscher-Levine mentioned another that may be able to address our needs. Dr. Prentice made a motion to not give approval for this project at this time until a detailed SOP is reviewed and approved by the IBC. The members agreed that no approval would be given at this time until a SOP is submitted to the IBC for approval. Also, work will not begin until the laboratory is setup and inspected, previous institutional IBC approval has been received, and training is completed.

Next, Ms. Ward and Dr. Orf gave an update on the liquid waste disposal issues for the prion lab. Meetings were conducted with state, county and city officials to discuss our waste inactivation and disposal procedures. Information and a revised SOP were sent to the officials so that their no discharge restriction can be reversed. Thus far, no feedback or decision as been made by the officials. In the meantime, waste is being stored in drums at the waste facility to avoid the high cost of disposal until a decision is finalized.

Furthermore, Ms. Ward discussed the NIH compliance letter that was sent to all registered IBCs. NIH will be conducting site inspections at some research facilities to ensure that the guidelines are followed. Also in the letter, IBC training was recommended for all members of the IBC. Ms. Ward discussed the PowerPoint presentation on NIH's website and will keep the members informed of courses that are held throughout the year. Also, Dr. Prentice suggested that someone from NIH can make a site visit to do a training presentation. The members agreed that this would be easier to fit into our schedules. Ms. Ward will research this option for the committee.

Lastly, the members decided to setup a date for the next meeting which will be April 11th at 3:30. In the meantime, the members can communicate by e-mail and phone to review and approve proposals unless a meeting is requested by Dr. Prentice.

The committee meeting was adjourned at approximately 4:40 PM.



FLORIDA ATLANTIC UNIVERSITY

777 GLADES ROAD, 112 CAMPUS OPERATIONS
BOCA RATON, FLORIDA 33431-0991
(561) 297-3129, FAX (561) 297-2210
Email: ehs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee
October 6, 2004 at 1:00 PM
123 Biomedical Science
Meeting Minutes

Members Present: Dr. David Binninger, Dr. Vijaya Iragavarapu-Charyulu, Dr. Zhongwei Li, Dr. Howard Prentice, Darlene Ward, Dr. Herbert Weissbach by Teleconference
Members Absent: Kathy Hoelscher-Levine, Dr. Herbert Rosenkranz, and Charles Williamson

Committee members introduced each other and thanked Dr. Li for joining the IBC. The committee members discussed Dr. Blanks' project entitled, Gene Transfer in Photoreceptor Cells. The committee liked the detailed information on the lentivirus vector design and construction and the safety features of the replication defective lentiviral vector system made by Dr. Planelle at the University of Utah. Dr. Prentice thought that the project specific virology training by Dr. Caputi would be advantageous for the lab to receive since the focus will be on retrovirus vectors. Ms. Ward spoke about her meeting with Dr. Blanks and the BL3 work practices that will be used in the project. The committee wanted to make sure the HIV medical surveillance requirement was something that will be made available and not mandatory forced on lab personnel. The members approved this project at BSL2 containment and BSL3 work practices.

Ms. Ward gave the members an update on the Scripps' Murine Scrapie project. The high autoclave perimeters for prions have been causing some problems in the lab such as; autoclave not shutting off, melting bags and stinking exhaust fumes. The committee needed to determine if the perimeters for the autoclave could be changed to the USDA recommendation of 134C for one hour instead of the CDC 132C for 4.5 hours. Since the CDC recommendation is from the 1999 edition and there is more recent government documentation that the autoclave perimeters to inactive prion have changed, the members approved the change in autoclave procedures. This change will extend the life of the autoclave and still be highly conservative since the waste which is not infectious to humans is also chemically treated and incinerated.

The liquid waste has also been an issue for this project. The microisolator cages are being decontaminated with bleach and the lab is generating about 20 gallons of liquid waste every three weeks. It was proposed that after neutralizing the liquid, it would be discarded down the drain. The Dept. of Health was OK with these procedures and so was the City of Boca (COB) until FLDEP got involved and at this time the COB will not allow sewer discharge of this waste. The decision was based on not enough information on environment impact and elevated concerns from a city resident. This waste is now being collected and sent out for incineration which is extremely costly and time consuming. In the meantime, more information was sent to the COB on other institutions that are doing similar procedures as FAU proposed. Also a meeting will be arranged with Scripps, EH&S and the other agencies involved with this decision to come up with a rational plan for this waste.

Furthermore, the members discussed the Scripps brochure on prion diseases. The committee liked the questions on the publication but wanted to include a section on research safety assurance procedures which was not in the brochure but the members felt it was something the public wanted to know.

Next, Ms. Ward let the members know that the FAU Biosafety Manual will be completed soon and send out for the committee's review and approval. The manual will be placed on the web for lab personnel.

Lastly, the Sunshine Project's IBC report was completed and each institution that is registered with the NIH was evaluated on transparency and IBC minutes. The report was sent out for members to review. Over two hundred research institutions were evaluated and FAU was 49th on the adequate to failed rating list. The report had an extremely negative stance on IBCs and the members thought that finding out what constitutes good minutes will be a more positive outcome of this report.

The committee meeting was adjourned at approximately 2:00 PM.



FLORIDA ATLANTIC UNIVERSITY

777 GLADES ROAD, 112 CAMPUS OPERATIONS
BOCA RATON, FLORIDA 33431-0991
(561) 297-3129, FAX (561) 297-2210
Email: ehs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee
May 26, 2004 at 2:00 PM
123 Biomedical Science
Meeting Minutes

Members Present: Dr. David Binninger, Ms. Kathy Hoelscher-Levine, Dr. Vijaya Iragavarapu-Charyulu, Dr. Howard Prentice, Darlene Ward, Dr. Herbert Weissbach
Others Present: Dr. Chris Baker

Committee members introduced each other and Dr. Prentice thanked everyone for coming to the meeting particularly Dr. Iragavarapu-Charyulu and Kathy Hoelscher-Levine for becoming new members of the IBC. The IBC also welcomed Dr. Chris Baker for coming to the meeting to answer questions on the Scripps project, entitled Experimental Model of Scrapie in the Mouse.

Dr. Weissbach asked Dr. Baker to explain the potential human risks involved with this project. Although there is no evidence of zoonotic transmission from scrapie, all procedures will be considered potentially infectious and performed in a Biosafety Cabinet (BSC) until denaturing process has occurred. Dr. Iragavarapu-Charyulu asked Dr. Baker what will be setup in the common lab area and to explain spill cleanup procedures if centrifuges are placed in the common area. Dr. Prentice asked Dr. Baker how much liquid waste will be generated on a weekly basis. Ms. Hoelscher-Levine wanted to make sure liquid waste disposal is approved by the Boca Raton's water department. A discussion ensued about liquid waste disposal and methods to deactivate solid waste as outlined by CDC, WHO and other publications.

Ms. Hoelscher-Levine was also concerned that the average person may not know about prions and the information on the internet may scare the community. The group discussed public perception and how the conservative approach to this project will help convince the public that we are treating this research with due care. Dr. Weissbach spoke about how the IBC will get most of the calls from the community and that Scripps should provide information for such inquiries. Dr. Binninger suggested a brochure or pamphlet similar to a CDC fact sheet.

The committee also discussed with Dr. Baker; transporting procedures for samples taken to Biomedical Science, BSC filters efficacy for prions, the necessity of medical surveillance for this project. After Dr. Baker left the meeting, the committee decided to give approval for this project only when the following conditions are met; 1) laboratory and vivarium space has been setup and inspected before work begins, 2) Dr. Richard Bessen has completed the protocol review, 3) details of waste disposal procedures are finalized, 4) restricted access, security procedures, and communication of hazards are outlined in SOP and strictly enforced, 5) centrifuges are housed in lab area and not in common area, 6) pamphlet/brochure is created for public relation inquiries.

Next, Ms. Ward spoke about the FAU/Scripps IBC oversight procedures that have been discussed with the Scripps' Research Office and NIH. The plan is to have FAU's IBC to be the first to review Scripps research projects and then have Scripps' IBC provide secondary oversight of these projects. The committee agreed with these procedures. Also, Ms. Ward discussed the Sunshine Project's latest endeavor to revoke federal funding from institutions that have not submitted their IBC minutes to them. The committee was given a copy of the NIH letter sent to all members outlining IBC requirements for public access to the minutes. Lastly, the members discussed the next quarterly meeting and changed the date to accommodate everyone.

The committee meeting adjourned at 3:30 PM.



FLORIDA ATLANTIC UNIVERSITY

777 GLADES ROAD, 112 CO, P. O. BOX 3091
BOCA RATON, FLORIDA 33431-0991

(561) 297-3129, FAX (561) 297-2210

Email: ehs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee

March 5, 2004 at 3:00 PM

123 Biomedical Science

Meeting Minutes

Members Present: Dr. David Binninger, Dr. Howard Prentice, Darlene Ward, Dr. Herbert Weissbach

Ms. Ward updated the committee of changes to the IBC members. Dr. Narayanan has stepped down to focus on his research endeavors and one community member, Nancy Segall, is relocating to another job. The infectious control director that has replaced Nancy Segall is interested in becoming a member of the IBC and Ms. Ward will meet with her to discuss the IBC purpose and procedures. The members also discussed faculty members that could replace Dr. Narayanan. Dr. Binninger suggested enlisting other members to use as alternates.

The members discussed Dr. Hartmann's research project to work with human blood and parvovirus B19. The committee approved the work to be done in accordance with Biosafety Level 2 work practices and containment.

Dr. Prentice and Ms. Ward spoke about the Sunshine Project's request to obtain copies of the IBC minutes. The members are concerned with the motives of this group and that the information they want can be taken out of context which could have a negative impact on FAU. Dr. Weissbach stated that more information should be obtained about the Sunshine Project's underlining agenda before we submit our minutes to them. The members agreed to approach legal counsel again to express their concerns on this matter. Ms. Ward will contact Sponsored Research's attorney for advice.

The committee discussed Dr. Esiobu's research work in conjunction with Dr. Kerr's proposal entitled, Marine Natural Products – A Resource to Combat Bioterrorism. The members have determined that the unknowns collected from the marine environment posed little risk to researchers but certain strains used as controls will require BL2 containment. After review is completed by members not present, approval will be granted for BL2 work practices and procedures.

Ms. Ward informed the committee on an additional area in Biomedical Science that will be zoned off for BL2 projects. The members discussed the desire for an enclosed ceiling in this area but the existing ventilation and available funding has not made this possible. Segregating the laboratory work space and adhering to safe work practices will make the 2nd floor more conducive for research with infectious agents.

The committee meeting was adjourned at 4:15 PM.



FLORIDA ATLANTIC UNIVERSITY

777 GLADES ROAD, 112 CO, P. O. BOX 3091
BOCA RATON, FLORIDA 33431-0991
(561) 297-3129, FAX (561) 297-2210
Email: ehs@fau.edu Web Page: www.fau.edu/ehs

Institutional Biosafety Committee
December 5, 2003 at 3:00 PM
123 Biomedical Science
Meeting Minutes

Members Present: Dr. David Binninger, Dr. Ram Narayanan, Dr. Howard Prentice, Dr. Herbert Rosenkranz, Nancy Segall, Darlene Ward, Dr. Herbert Weissbach, and Charles Williamson.

Committee members were introduced and the committee thanked Dr. Rosenkranz and the community members, Nancy Segall and Charles Williamson, for joining the IBC.

Ms. Ward discussed the DOD inspection results from Zhongwei Li's biodefense project and stated that he has been approved by the Army to start working on the project. Dr. Li has hired an assistant and she has also been cleared by DOD to work on this project. Furthermore, medical surveillance has been initiated for both researchers and the laboratory ventilation is being adjusted so airflow is balanced with the ducted biosafety cabinet.

The IBC NIH registration procedure was discussed with the committee and a copy of the NIH acknowledgment letter was given to the members.

The committee went over the research projects that were reviewed this year by the IBC. Dr. Prentice spoke about the review process and stated that certain projects do not need to have full committee review but will be reviewed and approved by the Chair and the BSO. The committee agreed with this process. Ms. Ward discussed the significance of Frank Mari's research proposal involving select agents and that he is under the exemption quantities of the new regulation, 42CFR73. Although he does not have to register with CDC, he needs to keep accurate inventory records and report to the IBC if he goes over the exemption limit. For security reasons, he must restrict access to the lab at all times and keep the select agents locked up in the lab.

The committee discussed Janet Blanks' research project to work with Adeno-Associated virus and Adenovirus vector systems. Dr. Prentice is assisting Dr. Blanks with the construct of the vectors which are replication defective. The committee discussed the BL2 lab that has been proposed for this work and Dr. Prentice explained that walls and a door will be put up on the second floor to segregate the BL1 and BL2 research areas. The committee agreed to approve this project at Biosafety Level 2 work practices and containment.

Lastly, the committee discussed quarterly meetings dates for next year. A tentative calendar will be setup for the IBC and sent out to the members.

The committee meeting was adjourned.